论文部分内容阅读
DNA拓扑异构酶(DNA topoisomerase,Topo)是细胞凋亡过程中关键的核内酶,Topo抑制剂通过作用于Topo抑制肿瘤的活性。然而在临床中,单独使用一种Topo抑制剂常常引发多药耐药性。研究证明,两种Topo抑制剂联合用药存在协同作用可以逆转这种多药耐药性,但这种联合与药物组配、肿瘤特点和给药顺序密切相关,本文就这种联合用药在逆转肿瘤多药耐药中的研究进展做一综述。
DNA topoisomerase (Topo) is a key nuclear enzyme in the process of apoptosis. Topo inhibitor suppresses tumor activity by acting on Topo. However, the use of a Topo inhibitor alone often leads to multidrug resistance in the clinic. Studies have shown that there is a synergistic effect of the two Topo inhibitors in combination can reverse this multidrug resistance, but this combination is closely related to drug combination, tumor characteristics and administration sequence. In this paper, Multidrug resistance in the research progress to be reviewed.